These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 28336955)

  • 1. Progress of antibody-based inhibitors of the HGF-cMET axis in cancer therapy.
    Kim KH; Kim H
    Exp Mol Med; 2017 Mar; 49(3):e307. PubMed ID: 28336955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical development of a humanized neutralizing antibody targeting HGF.
    Kim H; Hong SH; Kim JY; Kim IC; Park YW; Lee SJ; Song SW; Kim JJ; Park G; Kim TM; Kim YH; Park JB; Chung J; Kim IH
    Exp Mol Med; 2017 Mar; 49(3):e309. PubMed ID: 28336956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. cMET in triple-negative breast cancer: is it a therapeutic target for this subset of breast cancer patients?
    Gaule PB; Crown J; O'Donovan N; Duffy MJ
    Expert Opin Ther Targets; 2014 Sep; 18(9):999-1009. PubMed ID: 25084805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. cMET as a potential therapeutic target in gastric cancer (Review).
    Teng L; Lu J
    Int J Mol Med; 2013 Dec; 32(6):1247-54. PubMed ID: 24141315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A neutralizable epitope is induced on HGF upon its interaction with its receptor cMet.
    Kim K; Hur Y; Ryu EK; Rhim JH; Choi CY; Baek CM; Lee JH; Chung J
    Biochem Biophys Res Commun; 2007 Mar; 354(1):115-21. PubMed ID: 17214965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The emerging role of MET/HGF inhibitors in oncology.
    Scagliotti GV; Novello S; von Pawel J
    Cancer Treat Rev; 2013 Nov; 39(7):793-801. PubMed ID: 23453860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A HGF/cMET autocrine loop is operative in multiple myeloma bone marrow endothelial cells and may represent a novel therapeutic target.
    Ferrucci A; Moschetta M; Frassanito MA; Berardi S; Catacchio I; Ria R; Racanelli V; Caivano A; Solimando AG; Vergara D; Maffia M; Latorre D; Rizzello A; Zito A; Ditonno P; Maiorano E; Ribatti D; Vacca A
    Clin Cancer Res; 2014 Nov; 20(22):5796-807. PubMed ID: 25212607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Higher cMET dependence of sacral compared to clival chordoma cells: contributing to a better understanding of cMET in chordoma.
    Lohberger B; Scheipl S; Heitzer E; Quehenberger F; de Jong D; Szuhai K; Liegl-Atzwanger B; Rinner B
    Sci Rep; 2021 Jun; 11(1):12466. PubMed ID: 34127734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the hepatocyte growth factor-cMET axis in cancer therapy.
    Blumenschein GR; Mills GB; Gonzalez-Angulo AM
    J Clin Oncol; 2012 Sep; 30(26):3287-96. PubMed ID: 22869872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of HGF/cMET expression prevents distant recurrence of rectal cancer after preoperative chemoradiotherapy.
    Saigusa S; Toiyama Y; Tanaka K; Yokoe T; Fujikawa H; Matsushita K; Okugawa Y; Inoue Y; Uchida K; Mohri Y; Kusunoki M
    Int J Oncol; 2012 Feb; 40(2):583-91. PubMed ID: 21922134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma.
    Phan LM; Fuentes-Mattei E; Wu W; Velazquez-Torres G; Sircar K; Wood CG; Hai T; Jimenez C; Cote GJ; Ozsari L; Hofmann MC; Zheng S; Verhaak R; Pagliaro L; Cortez MA; Lee MH; Yeung SC; Habra MA
    Cancer Res; 2015 Oct; 75(19):4131-42. PubMed ID: 26282167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting c-MET/HGF signaling pathway in upper gastrointestinal cancers: rationale and progress.
    Gholamin S; Fiuji H; Maftouh M; Mirhafez R; Shandiz FH; Avan A
    Curr Drug Targets; 2014; 15(14):1302-11. PubMed ID: 25382190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ovarian cancer ascites enhance the migration of patient-derived peritoneal mesothelial cells via cMet pathway through HGF-dependent and -independent mechanisms.
    Matte I; Lane D; Laplante C; Garde-Granger P; Rancourt C; Piché A
    Int J Cancer; 2015 Jul; 137(2):289-98. PubMed ID: 25482018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Therapeutic Potential of Targeting the HGF/cMET Axis in Ovarian Cancer.
    Moran-Jones K
    Mol Diagn Ther; 2016 Jun; 20(3):199-212. PubMed ID: 27139908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. cMet agonistic antibody attenuates apoptosis in ischaemia-reperfusion-induced kidney injury.
    An JN; Li L; Lee J; Yu SS; Lee J; Kim YC; Kim DK; Oh YK; Lim CS; Kim YS; Kim S; Yang SH; Lee JP
    J Cell Mol Med; 2020 May; 24(10):5640-5651. PubMed ID: 32239661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the hepatocyte growth factor/Met pathway in cancer.
    De Silva DM; Roy A; Kato T; Cecchi F; Lee YH; Matsumoto K; Bottaro DP
    Biochem Soc Trans; 2017 Aug; 45(4):855-870. PubMed ID: 28673936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel rabbit anti-hepatocyte growth factor monoclonal neutralizing antibody inhibits tumor growth in prostate cancer cells and mouse xenografts.
    Yu Y; Chen Y; Ding G; Wang M; Wu H; Xu L; Rui X; Zhang Z
    Biochem Biophys Res Commun; 2015 Aug; 464(1):154-60. PubMed ID: 26093299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A receptor-antibody hybrid hampering MET-driven metastatic spread.
    Modica C; Basilico C; Chiriaco C; Borrelli N; Comoglio PM; Vigna E
    J Exp Clin Cancer Res; 2021 Jan; 40(1):32. PubMed ID: 33446252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer.
    Takeuchi S; Wang W; Li Q; Yamada T; Kita K; Donev IS; Nakamura T; Matsumoto K; Shimizu E; Nishioka Y; Sone S; Nakagawa T; Uenaka T; Yano S
    Am J Pathol; 2012 Sep; 181(3):1034-43. PubMed ID: 22789825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors.
    Burgess T; Coxon A; Meyer S; Sun J; Rex K; Tsuruda T; Chen Q; Ho SY; Li L; Kaufman S; McDorman K; Cattley RC; Sun J; Elliott G; Zhang K; Feng X; Jia XC; Green L; Radinsky R; Kendall R
    Cancer Res; 2006 Feb; 66(3):1721-9. PubMed ID: 16452232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.